Trials / Sponsors / Stephan Grupp MD PhD
Stephan Grupp MD PhD
Academic / Other · 8 registered clinical trials — 8 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia (AML) | Phase 1 | 2026-04-01 |
| Recruiting | Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases Systemic Lupus Erythematosus, Systemic Sclerosis | Phase 2 | 2026-03-01 |
| Recruiting | PHOX2B PC-CAR T Cells for Relapsed Neuroblastoma Refractory Neuroblastoma, Relapsed Neuroblastoma, High-Risk Neuroblastoma | Phase 1 | 2025-06-20 |
| Recruiting | Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma T-Cell Acute Lymphoblastic Leukemia/Lymphoma | Phase 1 | 2025-04-29 |
| Recruiting | GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma and Metastatic Retinoblastoma Refractory Neuroblastoma, Relapsed Neuroblastoma, High-risk Neuroblastoma | Phase 1 | 2023-05-23 |
| Recruiting | Co-administration of CART22-65s and huCART19 for B-ALL B-cell Acute Lymphoblastic Leukemia, B Lineage Lymphoblastic Lymphoma | Phase 1 / Phase 2 | 2023-01-25 |
| Recruiting | Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Pr B Cell Acute Lymphoblastic Leukemia (B-ALL), B Lineage Lymphoblastic Lymphoma | Phase 1 / Phase 2 | 2022-09-20 |
| Recruiting | Orphan Indications for CD19 Redirected Autologous T Cells Pediatric and Young Adult Patientswith Hypodiploid or t(17;19) B-ALL, Infants With Very High Risk KMT2A B-ALL, Patients With Central Nervous System Relapse Who Did Not Receive Cranial Radiation or Bone Marrow Transplantation | Phase 2 | 2020-03-12 |